Molecular Express announces award of STTR Phase I funding from the National Institutes of Health to develop a liposomal nicotine vaccine Print
Written by Administrator   
Thursday, 16 February 2012 11:47

Nicotine is the most widely used, readily available legal psychostimulant in the world and is highly addictive.  Current nicotine addiction treatments include nicotine replacement therapies, but this approach has yielded only modest results.  Molecular Express, Inc., in collaboration with Professor Kim Janda at The Scripps Research Institute, will engineer a liposomal nicotine vaccine through which an individual’s immune system will generate antibodies to sequester the nicotine in the bloodstream. 

Last Updated on Thursday, 22 March 2012 09:49